Go to deals
Healthcare

Kent Pharmaceuticals Limited has been acquired by DCC Plc

December 2012 — Dublin-based support services company, DCC plc, has acquired 100% of Kent Pharmaceuticals Ltd., the UK's largest independent generic pharmaceuticals manufacturer, for US$93 million.

DCC is a sales, marketing, distribution and business support services company. It operates in five segments: DCC Energy, DCC SerCom, DCC Healthcare, DCC Environmental, and DCC Food & Beverage.

DCC plans to combine Kent Pharmaceuticals with its healthcare division, DCC Healthcare, to create a pharma business with aggregate revenues approaching US$247 million and to become a leader in the British and Irish generic pharmaceutical market. Mike Overy, Kent Pharmaceutical’s managing director, said: “The shareholders believe this transaction provides a fantastic opportunity to continue the growth and development of Kent Pharmaceuticals with a partner that is committed to expanding into the generic pharmaceutical market.”

Our role in the transaction

Oaklins Cavendish, based in the UK, advised Kent Pharmaceuticals in this transaction. There had been a significant amount of consolidation in the sector in recent months and this deal creates a substantial UK generic pharmaceutical business with excellent international expansion opportunities.

Parties

Talk to the deal team

Lord Leigh of Hurley

Managing Partner
London, United Kingdom
Oaklins Cavendish

Michael Jewell

Partner
London, United Kingdom
Oaklins Cavendish

Related deals

Medicija has acquired Saulės Šeimos Medicinos Centras
Healthcare

Medicija has acquired Saulės Šeimos Medicinos Centras

Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.

Learn more
Quimpharma has completed the divestiture of a product portfolio to Megalabs
Healthcare

Quimpharma has completed the divestiture of a product portfolio to Megalabs

Quimpharma has completed the divestiture of a product portfolio to Megalabs México.

Learn more
IXICO has completed a fundraising
Healthcare

IXICO has completed a fundraising

IXICO plc, a specialist in AI-driven neuroimaging analytics, has completed a US$13.5 million gross capital raise. The funds will be used to support the company’s tech bio strategy, which will see IXICO partner its platform to maximize its potential.

Learn more